Latest News for: psychopharmacological
Edit
Reunion Neuroscience Announces Publication of RE104 Phase 1 Data in The Journal of Clinical Psychopharmacology
Nasdaq Globe Newswire 22 Jul 2025
-- Phase 1 Data Highlight RE104 Favorable Safety Profile and Short Duration Psychoactive Experience --. -- Topline Results from RECONNECT Phase 2 Trial of RE104 in Postpartum Depression (PPD) Anticipated in Q3 2025 -- ... .
Edit
Hearings, Meetings, Proceedings, etc.: Psychopharmacologic Drugs Advisory Committee, Supplemental New Drug Application 205422/S-012 for Rexulti (brexpiprazole) Tablets (The eRulemaking Program)
Public Technologies 17 Jun 2025
Psychopharmacologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Supplemental New Drug Application (sNDA) 205422/S-012 for REXULTI (brexpiprazole) Tablets.
Edit
Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing ...
Business Wire 29 May 2025
... of Clinical Psychopharmacology (ASCP) Annual Meeting, in Scottsdale, Arizona, held May 27-30, 2025.
Edit
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
Pharmiweb 29 May 2025
... Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting in Scottsdale, Arizona.
Edit
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 (Nxera Pharma Co Ltd)
Public Technologies 29 May 2025
announced that it had presented new positive data from the Phase 2 study of NBI-1117568 in adults with schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting in Scottsdale, Arizona.
Edit
May 28, 2025Suven Life Sciences to make two presentations at the American Society of Clinical Psychopharmacology (Suven Life Sciences Limited)
Public Technologies 28 May 2025
Suven Life Sciences to make two presentations at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting in Scottsdale, Arizona, USA.
Edit
Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
PR Newswire 28 May 2025
These results were shared as an oral presentation and poster at the American Society of Clinical Psychopharmacology 2025 Annual Meeting in Scottsdale, Arizona.
Edit
Hastings Tribune
27 May 2025
Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual
Hastings Tribune
27 May 2025
Edit
Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
Nasdaq Globe Newswire 27 May 2025
Edit
Hastings Tribune
23 May 2025
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
Hastings Tribune
23 May 2025
Edit
GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting (Form 6-K) (GH Research plc)
Public Technologies 15 May 2025
) GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting.
- 1